passages: 1125
passages: document
passages: Local immunotherapy by inhalation of a powder extract in asthma due to house dust mite Dermatophagoides pteronyssinus : a double-blind comparison with parenteral immunotherapy . To verify the efficacy and the tolerability of local immunotherapy ( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with parenteral immunotherapy ( PI ) by injection , 10 patients with asthma due to HDM were studied in a blind fashion . 5 patients ( Group A ) underwent LI and subcutaneous injections of placebo , 5 patients ( Group B ) underwent PI and inhalation of lactose for 6 months . In both groups each inhalation was preceded by premedication with disodium cromoglycate ( DSCG ) ( 40 mg ) . In Group A a significant decrease in symptoms score and in peak expiratory flow ( PEF ) -derived parameters was observed already after 3 months of treatment , and 2 patients lost the late component of the bronchial response to the challenge with HDM . No significant variation was found in bronchial responsiveness to methacholine and ultrasonically nebulized distilled water ( UNDW ) and in immunologic humoral and cellular parameters in peripheral blood after treatment in either group . No local important adverse reactions were observed in Group A and no systemic side effects were observed in either group . We conclude that LI is as effective as PI , but more rapid in its action , in the treatment of asthma due to HDM . Moreover , LI is locally well tolerated , providing DSCG is inhaled before each therapeutic inhalation , and does not induce systemic side effects .
entities: 1126
entities: Intervention_Pharmacological
entities: immunotherapy
entities: 1127
entities: Intervention_Pharmacological
entities: immunotherapy
entities: 1128
entities: Intervention_Pharmacological
entities: local immunotherapy
entities: 1129
entities: Intervention_Pharmacological
entities: powder extract of house dust mite ( HDM )
entities: 1130
entities: Intervention_Pharmacological
entities: parenteral immunotherapy ( PI )
entities: 1131
entities: Intervention_Control
entities: placebo
entities: 1132
entities: Intervention_Control
entities: lactose
entities: 1133
entities: Intervention_Pharmacological
entities: disodium cromoglycate ( DSCG )
entities: 1134
entities: Outcome_Other
entities: efficacy
entities: 1135
entities: Outcome_Other
entities: tolerability
entities: 1136
entities: Outcome_Physical
entities: symptoms score
entities: 1137
entities: Outcome_Physical
entities: peak expiratory flow ( PEF ) -derived parameters
entities: 1138
entities: Outcome_Physical
entities: bronchial response
entities: 1139
entities: Outcome_Physical
entities: bronchial responsiveness
entities: 1140
entities: Outcome_Physical
entities: immunologic humoral and cellular parameters in peripheral blood
entities: 1141
entities: Outcome_Adverse-effects
entities: local important adverse reactions
entities: 1142
entities: Outcome_Adverse-effects
entities: systemic side effects
entities: 1143
entities: Outcome_Adverse-effects
entities: systemic side effects .
entities: 1144
entities: Participant_Sample-size
entities: 10
entities: 1145
entities: Participant_Condition
entities: patients with asthma due to HDM